In HER2 positive breast cancer cells AS1842856 restores Lapatinib sensitivity by reducing the FOXO1-mediated MYC upregulation [71] and in ovarian cancer cells AS1842856 prevents the FOXO1-induced senescence by inhibiting the progestin-induced p21 expression [72]. The gene discussed is MYC; the disease is breast carcinoma.